Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice.
作者信息
Neven N, Vis M, Voskuyl A E, Wolbink G J, Nurmohamed M T, Dijkmans B A C, Lems W F
出版信息
Ann Rheum Dis. 2005 Apr;64(4):645-6. doi: 10.1136/ard.2004.028597.
Abstract
摘要
相似文献
1
Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice.
Ann Rheum Dis. 2005 Apr;64(4):645-6. doi: 10.1136/ard.2004.028597.
2
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Ann Rheum Dis. 2004 Dec;63(12):1538-43. doi: 10.1136/ard.2004.024737. Epub 2004 Jul 8.
3
The yin and yang of tumor necrosis factor inhibitors.
Cleve Clin J Med. 2006 Mar;73(3):251-6. doi: 10.3949/ccjm.73.3.251.
4
Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab.
Rheumatology (Oxford). 2003 Jun;42(6):800-2. doi: 10.1093/rheumatology/keg187.
5
Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy.
Intern Med. 2006;45(17):991-2. doi: 10.2169/internalmedicine.45.0156. Epub 2006 Oct 2.
6
Infliximab: additional safety data from an open label study.
J Rheumatol. 2002 Apr;29(4):647-9.
7
Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab).
J Clin Rheumatol. 2005 Apr;11(2):119-20. doi: 10.1097/01.rhu.0000158527.20518.30.
8
Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.
Rheumatology (Oxford). 2003 May;42(5):702-3. doi: 10.1093/rheumatology/keg160.
9
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii30-3. doi: 10.1136/ard.62.suppl_2.ii30.
10
Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor.
Respir Med. 2004 Feb;98(2):123-5. doi: 10.1016/j.rmed.2003.09.004.
引用本文的文献
1
Case Report: Development of medication-related osteonecrosis of the jaw in a patient on long-term infliximab therapy.
Front Oral Health. 2024 Jul 9;5:1427060. doi: 10.3389/froh.2024.1427060. eCollection 2024.
2
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
Immunotherapy. 2013 Mar;5(3):265-99. doi: 10.2217/imt.13.10.
3
Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure.
Clin Rheumatol. 2012 Feb;31(2):211-7. doi: 10.1007/s10067-011-1803-5. Epub 2011 Jul 1.
4
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
Ann Rheum Dis. 2011 Jul;70(7):1208-15. doi: 10.1136/ard.2011.153023. Epub 2011 Apr 8.
5
[Infectious complications of biologic therapy in patients with rheumatoid arthritis].
Z Rheumatol. 2010 Dec;69(10):879-88. doi: 10.1007/s00393-010-0677-2.
6
Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.
Drugs. 2008;68(5):591-606. doi: 10.2165/00003495-200868050-00003.
7
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18.
8
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Ann Rheum Dis. 2006 Jun;65(6):746-52. doi: 10.1136/ard.2005.045062. Epub 2005 Dec 8.
Zotero 插件